Friday, May 30, 2025

Latest

DiagnaMed Begins Test Launch of CERVAI

FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.

A test launch is currently underway for CERVAI, which has been deemed as a world-first consumer brain health and wellness AI solution. The test is being conducted by the University of Miami’s Comprehensive Center for Brain Health.

“We are creating momentum for the upcoming commercial launch of CERVAI, a world-first consumer brain health and wellness solution that estimates brain age and provides a brain health score, and being tested at a reputable University brain health center serves as a validation of CERVAI™’s potential in providing a unique service to clinics seeking a solution that helps bridge the gaps in physical and cognitive health while enhancing client engagement and design personalized interventions in improving overall brain health,” commented Fabio Chianelli, CEO of DiagnaMed Holdings.

The launch marks a significant milestone for DiagnaMed Holdings (CSE: DMED), whom has been developing the solution hand in hand with that of the University of Miami’s Miller School of Medicine. CERVAI has been developed to assess risk levels for the development of Alzheimer’s and other neurological issues through the use of a series of tests.

These tests produce three results, referred to as a Resilience Index, a Vulnerability Index, and a Number-Symbol Coding Task. When brought together, these results assist in assessing a patients risk for developing neurological issues by providing a snapshot of brain health.

A cross-sectional study previously conducted by the University that tested 230 participants identified that the methodology used by CERVAI demonstrated that individuals with abnormal test scores were 95.7% likely to be impaired, with a misclassification rate of 9.7%. The methodology is said to have outperformed the Montreal Cognitive Assessment, an industry standard in the area of early detection of mild cognitive impairments that has been in use since 2000.

Initial testing of CERVAI will focus on evaluating the brain health assessment portion of the tool.

A test pilot program meanwhile is open at 25 clinics across Canada and the US.

DiagnaMed Holdings last traded at $0.03 on the CSE.


FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

First Majestic Makes Second Major Discovery At Santa Elena In Just A Year

Related News

DiagnaMed Looks To Obtain Approval For Brain Age Clinical Tool In Q4

DiagnaMed Holdings (CSE: DMED) is moving towards obtaining regulatory approval for its Brain Age clinical...

Tuesday, January 31, 2023, 10:13:10 AM

DiagnaMed Launches Brain Age Brain Health AI Tool In Canada

DiagnaMed Holdings (CSE: DMED) has officially launched its Brain Age Brain Health AI solution in...
Tuesday, April 23, 2024, 09:22:20 AM

DiagnaMed Launches Division For Generative AI Healthcare Applications

FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings. A new division has been established by...

Wednesday, May 10, 2023, 11:14:40 AM

DiagnaMed Opens Enrollment For Healthcare Provider Network For Brain Health Platform

DiagnaMed Holdings (CSE: DMED) is moving forward with the commercialization of CERVAI, its brain health...
Tuesday, October 3, 2023, 09:08:43 AM

DiagnaMed Focuses On Brain Health AI Platform Development

DiagnaMed Holdings (CSE: DMED) appears to be going all in on artificial intelligence. The drug...

Tuesday, February 14, 2023, 08:04:57 AM